The economics of PCSK-9 inhibitors.
Publication
, Journal Article
Schulman, KA; Reed, SD
Published in: Am Heart J
July 2017
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Am Heart J
DOI
EISSN
1097-6744
Publication Date
July 2017
Volume
189
Start / End Page
200 / 201
Location
United States
Related Subject Headings
- PCSK9 Inhibitors
- Middle Aged
- Male
- Humans
- Female
- Drug Costs
- Cardiovascular System & Hematology
- Atherosclerosis
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal
Citation
APA
Chicago
ICMJE
MLA
NLM
Schulman, K. A., & Reed, S. D. (2017). The economics of PCSK-9 inhibitors. Am Heart J, 189, 200–201. https://doi.org/10.1016/j.ahj.2017.05.001
Schulman, Kevin A., and Shelby D. Reed. “The economics of PCSK-9 inhibitors.” Am Heart J 189 (July 2017): 200–201. https://doi.org/10.1016/j.ahj.2017.05.001.
Schulman KA, Reed SD. The economics of PCSK-9 inhibitors. Am Heart J. 2017 Jul;189:200–1.
Schulman, Kevin A., and Shelby D. Reed. “The economics of PCSK-9 inhibitors.” Am Heart J, vol. 189, July 2017, pp. 200–01. Pubmed, doi:10.1016/j.ahj.2017.05.001.
Schulman KA, Reed SD. The economics of PCSK-9 inhibitors. Am Heart J. 2017 Jul;189:200–201.
Published In
Am Heart J
DOI
EISSN
1097-6744
Publication Date
July 2017
Volume
189
Start / End Page
200 / 201
Location
United States
Related Subject Headings
- PCSK9 Inhibitors
- Middle Aged
- Male
- Humans
- Female
- Drug Costs
- Cardiovascular System & Hematology
- Atherosclerosis
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal